Nalbuphine, a mixed kappa(1) and kappa(3) analgesic in mice Journal Article


Authors: Pick, C. G.; Paul, D.; Pasternak, G. W.
Article Title: Nalbuphine, a mixed kappa(1) and kappa(3) analgesic in mice
Abstract: Nalbuphine is a mixed opioid agonist/antagonist analgesic. It labels mu receptors most potently where it acts as an antagonist. Nalbuphine is analgesic in the tail-flick assay after systemic (ED50, 41.8 mg/kg s.c.), i.c.v. (ED50, 21.3 μg) or intrathecal administration (ED50, 11.2 μg). Analgesia elicited by systemic nalbuphine was reversed by nor- binaltorphimine, but not by β-funaltrexamine or naltrindole despite their ability to antagonize morphine and [D-Pen2, D-Pen5]enkephalin analgesia, respectively. This insensitivity toward β-funaltrexamine and naltrindole argued strongly against either a mu or delta component of analgesia. Nor- binaltorphimine antagonized systemic nalbuphine analgesia over 10-fold more potently after intrathecal injection of the antagonist than after i.c.v. administration, implying a role for kappa1 receptors at the spinal level. The presence of analgesic cross-tolerance between nalbuphine and both naloxone benzoylhydrazone and nalorphine indicated an analgesic role for kappa3 receptors, which act supraspinally. Additional studies revealed synergistic interactions between spinal kappa1 and supraspinal kappa3 receptors when nalbuphine was given both intrathecally and i.c.v. In conclusion, these studies suggest that nalbuphine elicits analgesia through a complex interaction of supraspinal kappa3 and spinal kappa1 mechanisms.
Keywords: controlled study; dose response; drug potentiation; nonhuman; mouse; animal; mice; animal experiment; dose-response relationship, drug; drug antagonism; drug mechanism; analgesia; hallucination; morphine sulfate; tail flick test; injections, spinal; naloxone; beta funaltrexamine; enkephalin[2,5 dextro penicillamine]; naltrindole; naltrexone; analgesic activity; receptor subtype; 3,4 dichloro n methyl n [2 (1 pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulfonate; dysphoria; nalbuphine; kappa opiate receptor; drug cross tolerance; narcotic antagonists; subcutaneous drug administration; receptors, opioid; intracerebroventricular drug administration; norbinaltorphimine; male; priority journal; article; nalorphine; receptors, opioid, kappa; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; intrathecal drug administration; quadazocine
Journal Title: Journal of Pharmacology and Experimental Therapeutics
Volume: 262
Issue: 3
ISSN: 0022-3565
Publisher: American Society for Pharmacology and Experimental Therapeutics  
Date Published: 1992-09-01
Start Page: 1044
End Page: 1050
Language: English
PUBMED: 1326621
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Citation Impact
MSK Authors
  1. Gavril W Pasternak
    414 Pasternak
  2. Chaim G. Pick
    14 Pick
  3. Dennis J. Paul
    17 Paul